Indications for: UNASYN
Susceptible skin and skin structure, intraabdominal, gynecologic infections.
Skin and Skin Structure Infections in Pediatric Patients
A controlled clinical trial evaluated the efficacy and safety of Unasyn for the treatment of skin and skin structure infections in pediatric patients. Patients received either Unasyn (n=60) or cefuroxime (n=39) intravenously. Results showed similar outcomes between both treatment arms.
Dose is given as ampicillin + sulbactam. Normal renal function (CrCl ≥30mL/min): 1.5–3g IM or IV every 6hrs; CrCl 15–29mL/min: 1.5–3g every 12hrs; CrCl 5–14mL/min: 1.5–3g every 24hrs.
Intraabdominal infections: not established. Dose is given as ampicillin + sulbactam. <1yr: not established. ≥1yr (<40kg): 300mg/kg per day IV in equally divided doses every 6hrs; usual max 14 days. ≥40kg: as adult.
History of cholestatic jaundice/hepatic dysfunction due to Unasyn. Penicillin, cephalosporin, or other β-lactam allergy.
Mononucleosis: not recommended. Discontinue if superinfection or hypersensitivity reactions occur, or if skin lesions progress. Hepatic impairment; monitor LFTs regularly. Pregnancy. Nursing mothers.
Broad-spectrum penicillin + β-lactamase inhibitor.
Potentiated by probenecid. Increased incidence of rash with allopurinol. May cause false (+) Clinitest, Benedict's or Fehling's soln.
Inj site reactions, diarrhea, rash, blood dyscrasias; C. difficile-associated diarrhea (evaluate if occurs), hypersensitivity or severe skin reactions (eg, SJS, TEN, dermatitis exfoliative, erythema multiforme, AGEP), hepatotoxicity.
- Renal. Half-life: ~1 hour.
Generic Drug Availability:
Vials (1.5g, 3g)—1